Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Tex Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,952,077

163 payments

Through program year 2023, Clinical Tex Research LLC is reported as receiving $4,952,077 in research payments, across 163 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $7,557 9
2022 Research $884,722 101
2021 Research $1,784,765 34
2020 Research $2,233,134 12
2019 Research $41,899 7

Breakdown

Who paid Research payments · program years 2019–2023
  1. Regeneron Pharmaceuticals, Inc. $4,851,188 149 payments
  2. Allergan Inc. $51,150 9 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $49,739 5 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $2,884,015 54 payments
  2. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 $1,535,356 31 payments
  3. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $380,229 10 payments
  4. Safety & Efficacy of Empa in patients with Acute H $31,728 2 payments
  5. A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease $28,219 27 payments
  6. A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $26,906 5 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants $23,369 27 payments
  8. A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $20,238 3 payments
  9. BI 767551 EX14870 Ph II III SARS COV 2 Ambulato $11,859 2 payments
  10. Empagliflozin for prevention of HHF and death afte $6,152 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record